Dako, Omnyx partner to develop clinical algorithms for digital pathology
Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology.
Dako, a world-leading provider of cancer diagnostic solutions such as pharmDx™, has entered into a collaboration with Bristol-Myers Squibb Company to develop pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with certain investigational cancer drug candidates under development by Bristol-Myers Squibb.